The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of iberdomide for the treatment of multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, briefly discusses the safety and efficacy of iberdomide for the treatment of multiple myeloma. Dr Popat first compares the mechanism of action of iberdomide with that of thalidomide, lenalidomide and pomalidomide, and then discusses the efficacy and tolerability of this novel agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
